Sonoma Pharmaceuticals Enters Market Issuance Sales Agreement with Ladenburg

Sonoma Pharmaceuticals has entered a market issuance sales agreement with Ladenburg. The company is a global healthcare firm that produces stabilized hypochlorous acid products for wound care, eye care, and other applications. Its product offerings include Lumacyn Clarifying Mist, Regenacyn Advanced Scar Gel, Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel, and Microcyn OTC Advanced Wound & Skin Cleanser.

Sonoma Pharmaceuticals has entered a market issuance sales agreement with Ladenburg, a global healthcare firm. The agreement marks a significant milestone for Sonoma Pharmaceuticals, which specializes in producing stabilized hypochlorous acid (HOCl) products for various applications, including wound care, eye care, and skincare. The company's product portfolio includes Lumacyn Clarifying Mist, Regenacyn Advanced Scar Gel, Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel, and Microcyn OTC Advanced Wound & Skin Cleanser.

This strategic partnership is expected to bolster Sonoma Pharmaceuticals' market presence and expand its reach in the global healthcare sector. Ladenburg's extensive network and expertise in the healthcare industry will provide Sonoma Pharmaceuticals with valuable insights and opportunities to penetrate new markets and enhance its product offerings.

The agreement comes at a time when the global HOCl market is experiencing rapid growth. According to a recent report, the market surged from $8.96 billion in 2024 and is projected to hit $11.80 billion by 2034, driven by the increasing demand for wellness, skincare, and animal care applications Vanderbilt Report: Full Alliance Group helps Power Hypochlorous Acid’s Breakout from Hospitals to the Global Consumer Market^[1].

Sonoma Pharmaceuticals' focus on stabilized HOCl products aligns with the growing trend of consumers seeking cleaner, safer, and sustainable wellness solutions. The company's portfolio of HOCl-based products, which are dermatologist-approved and effective against various skin conditions, is poised to benefit from this shift in consumer preferences.

The market issuance sales agreement with Ladenburg is a testament to Sonoma Pharmaceuticals' commitment to innovation and its ability to capitalize on the growing demand for HOCl-based solutions. The company's robust contract manufacturing infrastructure and expertise in producing stabilized HOCl products position it well to meet the increasing demand for these products in various healthcare sectors.